ROCKVILLE, Md., Oct. 24, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it has named Bob Repella as Senior Vice President, Chief Commercial Officer of the company.
Mr. Repella has more than 25 years of experience in the biotech/pharmaceutical industry, including senior-level leadership roles in global marketing, sales, new product development and commercial operations.
“We are very pleased to welcome Bob to the Vanda team,” said Mihael Polymeropoulos, M.D., President and CEO of Vanda. “His depth of industry experience and proven track record across a wide spectrum of therapeutic areas are expected to be pivotal to the commercial success of Vanda’s product pipeline.”
Prior to joining Vanda, Mr. Repella was Senior Vice President of Pharmaceutical Operations for the America’s Region at Cephalon, Inc. In this position, he was responsible for all commercial operations in North and South America, including brand marketing, sales, managed markets and new product planning. This included oversight of all therapeutic categories (CNS, Oncology and Pain), partnership agreements and the Mepha generics division.
Before joining Cephalon, Mr. Repella was Executive Vice President and General Manager of the Biopharma Business Unit for Wyeth Pharmaceuticals. In this position, he was responsible for the global portfolio of products across Wyeth’s immunology, oncology and hemophilia franchises. During his 16 years at Wyeth, Mr. Repella served in various roles in both marketing and sales, including Executive Vice President Pharmaceutical Sales, Marketing and Operations; Senior Vice President, Pharmaceutical Sales; and Vice President, Global Business Manager, Enbrel®.
Earlier in his career, Mr. Repella held positions with Johnson & Johnson’s McNeil Pharmaceutical Division, Merck & Co., Inc. and Eli Lilly & Co. Mr. Repella received his Bachelors Degree in Pharmacy from Rutgers University and a Masters in Business Administration from Temple University.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders. For more on Vanda, please visit http://www.vandapharma.com/.
Media Contact:
Cristina Murphy
+1-240-599-4500
cristina.murphy@vandapharma.com
SOURCE Vanda Pharmaceuticals Inc.
